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OBJECTIVE: To assess the feasibility of using interna-
tional disease-specific, cross-sectional databases for phar-
macoeconomic research.
METHODS: We evaluated several large international
cross-sectional, disease-specific databases for their appro-
priateness in early and late phase research. A migraine da-
tabase is presented as an example. The migraine database
contained 699 physicians and 8,537 subjects in 6 coun-
tries.
RESULTS: Data elements could be used in modeling, cost
of care, patient segmentation, and cost-effectiveness stud-
ies. For example, average resource use for France, Ger-
many and the US for PCP visits (over the previous 12
months) was 3.3, 4.0, and 4.3 days, respectively. Inpatient
hospitalization days for the same countries were 0.1, 0.1
and 1.9, respectively. For modeling purposes, transition
probabilities could be based on the length of the migraine
attack (in France): 25 hours without treatment and 7
hours with treatment. Lost work time, important to mi-
graineurs, was examined by severity group. During the
previous 6 months lost time from work for moderate mi-
graines for France, Germany and the US was 11.4, 4.5,
and 4.8, respectively. For severe patients, lost work time
was 6.6, 6.2, and 7.8 days, respectively.
CONCLUSIONS: International databases offer some in-
formation useful for PE research. Their strength relies on
the large number of patients and the validity of the data is
higher than using experts to estimate resource utilization.
In addition, the international aspect of the database facili-
tates cross-country comparisons and the adaptation of
models to local settings.
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This study reports the results of a long-term cost effective-
ness analysis of riluzole in the treatment of amyotrophic
lateral sclerosis (ALS) in the United Kingdom. Long term
analysis was carried out using Markov modelling extrapo-
lating the transition probabilities derived from clinical trial
data. The implications of life extension offered by riluzole
were assessed in terms of the time spent in each health
state which ALS patients experience. This data was taken
from a cohort of 954 patients drawn from a large random-
ized, double blind, placebo controlled, multi-center trial
between 1992 and 1994.
RESULTS: Findings suggest that riluzole is effective in
prolonging life and that a larger proportion of patients
treated with riluzole will stay longer in states where func-
tional status is least impaired. The additional life expect-
ancy of the intervention over the three-year period sug-
gests that treatment of three patients for three years would
result in obtaining one additional life-year. Riluzole offsets
approximately half the additional costs of treatment
through extending the time that patients spend in the
milder phases. Therefore, cost per unadjusted additional
life-year gained was estimated at £8,587 over the expected
lifetime of ALS patients. The findings also show that incre-
mental cost figures are not sensitive to the cost of health
states.
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OBJECTIVES: As part of a multi-national, observational
investigation of the quality of life and economic correlates
of recognized major depression in primary care (the LIDO
study), to develop a research method for the collection of
a) individual health care service utilisation and associated
costs data, and b) site-level socio-demographic and service
profiles.
METHODS: Alternative approaches to the collection and
aggregation of data relating to the utilisation, cost, struc-
ture and provision of local health services were reviewed,
together with relevant existing instruments. An iterative
process of cross-cultural validation was pursued in order
to ensure standardized definitions and semantic equiva-
lence of services across sites.
RESULTS: Three sets of instrumentation were developed:
1) a “local socio-demographic and service profile” sched-
ule giving data on key socio-demographic indicators and
primary/secondary care service characteristics at the local,
regional and national level of each participating site; 2) an
interviewer-led resource utilisation questionnaire contain-
ing internationally comparable items of potential service
receipt (subsequently translated into local site languages
and incorporated into the assessment of each recruited
study subject); and 3) a set of unit cost templates for all
itemized services, based on a common protocol and stan-
dardized methodology. Both “purchasing power parities”
and a “market basket” approach were used (and com-
pared) as the basis for converting national service costs
into a single currency for the purposes of pooled analyses.
A conceptual model depicting the inter-relationship be-
tween costs, depressive symptoms and quality of life was
constructed in order to generate and structure study hy-
potheses and modes of analysis.
CONCLUSION: Cross-cultural comparison of health ser-
vice utilisation and costs is complicated by the heterogene-
ity of service systems and the need to reflect the contexts
within which people live and receive their care. In order to
be locally meaningful yet internationally comparable, a
carefully constructed approach towards data collection is
required.
